Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 27, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 1,000,000 ordinary shares of 25 pence each.
- Purchase Price: 1,456.1106 pence per share.
- Treasury Shares Held: 146,479,678 shares (post-transaction).
- Shares in Issue: 5,821,618,983 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback authorized by shareholders at the Annual General Meeting on May 25, 2005. The company executed the purchase on February 27, 2006, and intends to hold the acquired shares in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase or subscribe for securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 1,000,000 share repurchase based on the disclosed price of 1,456.1106 pence.
- Confirm the updated total share capital structure (5,821,618,983 shares in issue plus 146,479,678 Treasury shares).
- Review the original shareholder authorization from the May 25, 2005 Annual General Meeting to ensure the repurchase was within approved limits.